Calithera Biosciences Inc (CALA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Calithera Biosciences Inc (CALA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8180
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Calithera Biosciences Inc (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company’s product pipeline includes CB-839, a glutaminase inhibitor in tumor metabolism to treat solid tumors; NCB001158, a small molecule arginase inhibitor based on tumor immunology technology that activates the body’s own immune system to attack and kill cancer cells for the treatment of hematology and oncology diseases; CB-280, a arginase inhibitor used for treating Cystic Fibrosis; CB-708, a CD73 inhibitor against immuno-oncology condidtions. The company works in collaboration with bio-pharmaceutical companies such as Incyte Corp, Bristol-Myers Squibb (BMS), and Mars Symbiosciences Inc. Calithera is headquartered in South San Francisco, California, the US.

Calithera Biosciences Inc (CALA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calithera Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Calithera Biosciences Raises USD14.5 Million in Venture Financing 10
Calithera Biosciences Raises USD16 Million in Venture Financing 11
Calithera Biosciences Raises US$35 Million In Series D Financing 12
Calithera Biosciences Raises US$2 Million In Series C Financing 14
Calithera Biosciences Raises Additional US$4 Million In Series B Financing 15
Partnerships 17
Calithera Biosciences Enters into Partnership with Pfizer 17
Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 18
ProTrials Research Enters into Agreement with Calithera Biosciences 19
Licensing Agreements 20
Incyte Enters into Licensing Agreement with Calithera Biosciences 20
Calithera Biosciences Enters into Licensing Agreement with Mars Symbioscience 22
Equity Offering 23
Calithera Biosciences to Raise up to USD50 Million in Public Offering of Shares 23
Calithera Biosciences Raises USD38 Million in Public Offering of Shares 24
Calithera Biosciences Raises USD80.5 Million in Public Offering of Shares 25
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 27
Calithera Biosciences Raises USD80 Million in IPO 29
Calithera Biosciences Inc – Key Competitors 31
Calithera Biosciences Inc – Key Employees 32
Calithera Biosciences Inc – Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Financial Announcements 34
Aug 07, 2018: Calithera Biosciences reports second quarter 2018 financial results and recent highlights 34
May 10, 2018: Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights 36
Mar 08, 2018: Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights 38
Nov 02, 2017: Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights 40
Aug 08, 2017: Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights 41
May 09, 2017: Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights 42
Mar 16, 2017: Calithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights 44
Corporate Communications 46
Oct 03, 2017: Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel 46
Sep 21, 2017: Calithera Biosciences Appoints Blake Wise to Board of Directors 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calithera Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calithera Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Calithera Biosciences Raises USD14.5 Million in Venture Financing 10
Calithera Biosciences Raises USD16 Million in Venture Financing 11
Calithera Biosciences Raises US$35 Million In Series D Financing 12
Calithera Biosciences Raises US$2 Million In Series C Financing 14
Calithera Biosciences Raises Additional US$4 Million In Series B Financing 15
Calithera Biosciences Enters into Partnership with Pfizer 17
Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 18
ProTrials Research Enters into Agreement with Calithera Biosciences 19
Incyte Enters into Licensing Agreement with Calithera Biosciences 20
Calithera Biosciences Enters into Licensing Agreement with Mars Symbioscience 22
Calithera Biosciences to Raise up to USD50 Million in Public Offering of Shares 23
Calithera Biosciences Raises USD38 Million in Public Offering of Shares 24
Calithera Biosciences Raises USD80.5 Million in Public Offering of Shares 25
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 27
Calithera Biosciences Raises USD80 Million in IPO 29
Calithera Biosciences Inc, Key Competitors 31
Calithera Biosciences Inc, Key Employees 32

List of Figures
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calithera Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Calithera Biosciences Inc (CALA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • National Shipping Company of Saudi Arabia (4030):企業の財務・戦略的SWOT分析
    National Shipping Company of Saudi Arabia (4030) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Auris Medical Holding AG (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding AG (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • BB&T Corporation:企業のM&A・事業提携・投資動向
    BB&T Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BB&T Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Pacira Pharmaceuticals Inc (PCRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Pacira Pharmaceuticals Inc (Pacira) discovers, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic indicated for infiltra …
  • WEC Energy Group Inc (WEC)-エネルギー分野:企業M&A・提携分析
    Summary WEC Energy Group, Inc. (WEC) is a diversified holding company that carries out the generation and distribution of electricity in southeastern Wisconsin, east central Wisconsin, northern Wisconsin, and Michigan's Upper Peninsula; and transports and distributes natural gas in the upper peninsu …
  • Itau Unibanco Holding SA:企業のM&A・事業提携・投資動向
    Itau Unibanco Holding SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Itau Unibanco Holding SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Murree Brewery Co. Ltd.:戦略・SWOT・企業財務分析
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Merus Labs International Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Merus Labs International Inc (Merus Labs International), formerly Merus Labs Inc, a subsidiary of Norgine BV, is a pharmaceutical company that provides medicinal products. The company offers products in the therapeutic areas of cardiovascular, oncology support, women's health, urology, and i …
  • Fortis Inc (FTS):企業の財務・戦略的SWOT分析
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • Premier Oil Plc (PMO):企業の財務・戦略的SWOT分析
    Premier Oil Plc (PMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Jyoti Structures Ltd (JYOTISTRUC)-エネルギー分野:企業M&A・提携分析
    Summary Jyoti Structures Ltd (JSL) is a turnkey engineering, procurement, and construction (EPC) services provider that designs, tests, manufactures, sources, constructs, and supplies transmission lines, substations, and microwave towers. It designs HVDC and river crossing transmission towers, subst …
  • Halozyme Therapeutics Inc (HALO):医療機器:M&Aディール及び事業提携情報
    Summary Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The company’s marketed product, Hylenex is an agent for drug and fluid …
  • Best Doctors Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Best Doctors Inc (Best Doctors), a subsidiary of Teladoc, Inc, is a healthcare service provider that offers medical services. The company provides services such as inter-consultation and critical care inter-consultation services for multi-trauma, spinal cord injuries, traumatic brain injurie …
  • National Reinsurance Corporation Of The Philippines:企業の戦略・SWOT・財務分析
    National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report Summary National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …
  • MediaValet Inc.:戦略・SWOT・企業財務分析
    MediaValet Inc. - Strategy, SWOT and Corporate Finance Report Summary MediaValet Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Hochdorf Holding AG (HOCN):企業の財務・戦略的SWOT分析
    Hochdorf Holding AG (HOCN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • QuickLogic Corp (QUIK):企業の財務・戦略的SWOT分析
    QuickLogic Corp (QUIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • AbbVie Inc (ABBV):企業の財務・戦略的SWOT分析
    AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cytox Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Cytox Ltd (Cytox) is a prognostic and diagnostic service provider that develops neurodegenerative disorders services. The company offers development of tests to identify individuals at risk of cognitive decline, Alzheimer’s disease and other dementias and its blood tests are used to predict …
  • SARIA AS GmbH & Co KG:企業の戦略的SWOT分析
    SARIA AS GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆